Adding pembrolizumab to chemotherapy significantly improved survival outcomes and response rate compared with chemo alone in patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the updated results of the KEYNOTE-859study presented at ESMO WCGIC 2023.
Treatment with tremelimumabplus durvalumab(STRIDE* regimen) continues to yield overall survival (OS) benefit at 4 years among patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib, according to the updated results of the HIMALAYA trial presented at ESMO WCGIC 2023.
In patients with HER-2-overexpressing metastatic or advanced gastric/gastroesophageal (G/GEJ) adenocarcinoma, a regimen comprising standard-of-care chemotherapy and a HER2-targeting peptide vaccine induced antibody responses that corresponded with tumour size reduction, according to an analysis of the HERIZON study which looked into the correlation between antibody responses and clinical outcomes.
In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.
In patients with locally advanced pancreatic cancer, treatment with intra-arterial gemcitabine leads to better survival and safety outcomes compared with standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023.
Topical diclofenac gel significantly reduced the incidence of hand-foot syndrome (HFS) in patients with gastrointestinal (GI) cancer receiving capecitabine, according to findings from the exploratory subgroup analysis of the D-ToRCH* trial.